Analysis of the medical insurance price of Osimertinib/Tagressa in 2025: How will patients benefit?

Osimertinib/Tagrisso (Osimertinib) is a third-generation EGFR-TKI targeted drug, mainly used to treat EGFR mutation-positive non-small cell lung cancer (NSCLC). Its indications include first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletion or exon 21 (L858R) mutation, and second-line treatment of patients with locally advanced or metastatic NSCLC with positive EGFR T790M mutation. Osimertinib can effectively delay tumor progression and improve patients' quality of life by precisely inhibiting the activity of EGFR mutant proteins, making it an important choice for targeted treatment of lung cancer.

In the domestic market, the original drug of osimertinib is widely available. The common specifications are80mg×30 tablets and 40mg×30 tablets. The price per box is about RMB 4,000 to 6,000 yuan. Although the price is higher, osimertinib has been included in the national medical insurance catalog, and patients can reimburse part of the cost through medical insurance, thus significantly reducing the financial burden. According to the latest medical insurance policy, the reimbursement ratio of osimertinib varies by region, and is usually reimbursed at 50%-70%, which means that the patient’s out-of-pocket portion may be reduced to less than 2,000 yuan, greatly improving the accessibility of the drug.

OutlookIn 2025, with the further optimization of medical insurance policies and the launch of generic drugs, the price of osimertinib is expected to decline further. In addition, the National Medical Insurance Administration continues to increase its support for innovative drugs, and more indications may be included in reimbursement in the future, such as adjuvant treatment for early-stage lung cancer. For patients, this not only means a reduction in treatment costs, but also means more treatment opportunities.

In general, osimertinib plays an important role in the treatment of EGFR mutation-positive non-small cell lung cancer, and its medical insurance reimbursement policy provides financial support to patients. With the improvement of medical insurance policies and the advancement of medical technology, more patients will be able to obtain efficient treatment drugs at lower costs in the future, bringing more hope to the fight against cancer.

Reference materials:https://go.drugbank.com/drugs/DB09330